Victory Capital Management
DYN icon

Victory Capital Management’s Dyne Therapeutics DYN Stock Holding History

Victory Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$961K Buy
52,980
+1,496
+3% +$25.8K ﹤0.01% 1859
2025
Q4 		$1.01M Buy
51,484
+1,382
+3% +$26.2K ﹤0.01% 1831
2025
Q3 		$634K Sell
50,102
-16,311
-25% -$186K ﹤0.01% 1997
2025
Q2 		$632K Buy
66,413
+7,002
+12% +$77.1K ﹤0.01% 2009
2025
Q1 		$621K Sell
59,411
-1,937
-3% -$27.7K ﹤0.01% 1973
2024
Q4 		$1.45M Buy
61,348
+30,811
+101% +$911K ﹤0.01% 1629
2024
Q3 		$1.1M Buy
30,537
+11,385
+59% +$453K ﹤0.01% 1742
2024
Q2 		$676K Buy
+19,152
New +$557K ﹤0.01% 1882

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Victory Capital Management's DYN Position: Q1 2026 in Review

Victory Capital Management increased its Dyne Therapeutics (DYN) stake by 2.9% in Q1 2026, buying an estimated $25.8K and bringing the position to 52,980 shares worth $961K. The position accounts for ﹤0.01% of the portfolio, ranked #1859.

Victory Capital Management first reported a position in DYN in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.45M in Q4 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Victory Capital Management held 52,980 shares of Dyne Therapeutics worth $961K as of Q1 2026.
  • Victory Capital Management bought 1,496 Dyne Therapeutics shares in Q1 2026, an estimated $25.8K.
  • Dyne Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #1859 holding.
  • Victory Capital Management first reported a position in Dyne Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Victory Capital Management's Dyne Therapeutics position peaked at $1.45M in Q4 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.